The NOR-TEST 2A trial was stopped after increased rates of ICH and mortality were seen in the group assigned to tenecteplase 0.4 mg/kg compared with the standard dose of alteplase.
Giving the bolus thrombolytic tenecteplase in a mobile stroke unit improved efficacy compared with the standard of care thrombolytic alteplase, without safety concerns, in the TASTE-A study.
A retrospective analysis suggests that recent NOAC use is not associated with increased risk for symptomatic intracranial hemorrhage after treatment with IV alteplase for acute ischemic stroke.
A prospective, observational study suggests that mobile stroke units are associated with lower stroke-related costs per quality-adjusted life year compared with standard care.
The thrombolytic tenecteplase may have a role in reestablishing blood flow in patients with large-vessel acute ischemic stroke up to 24 hours after stroke onset, a new trial from China suggests.